1-chloro-2-(3,4,5-trimethoxyphenyl)ethane | 50987-66-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-chloro-2-(3,4,5-trimethoxyphenyl)ethane
• 英文别名: 3,4,5-trimethoxyphenethyl chloride；5-(2-chloro-ethyl)-1,2,3-trimethoxy-benzene；3,4,5-trimethoxy-phenethyl chloride；2-Chlor-1-(3,4,5-Trimethoxy-phenyl)-aethan；3,4,5-Trimethoxy-phenethylchlorid；5-(2-Chloroethyl)-1,2,3-trimethoxybenzene
• CAS: 50987-66-1
• 化学式: C₁₁H₁₅ClO₃
• 分子量: 230.691
• InChiKey: LGAAWMCNBATHDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2909309090

反应信息

• 作为反应物：
  描述：

  1-chloro-2-(3,4,5-trimethoxyphenyl)ethane 在 sodium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 O-<2-(3,4,5-Trimethoxyphenyl)-ethyl>-hydroxylamin
  参考文献：
  名称：

  羟胺衍生物：中枢神经系统兴奋剂。

  摘要：

  DOI：

  10.1021/jm50017a005
• 作为产物：
  描述：

  3,4,5-三甲氧基苯乙酸 在 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 以 吡啶 为溶剂， 生成 1-chloro-2-(3,4,5-trimethoxyphenyl)ethane
  参考文献：
  名称：

  含有哌嗪或高哌嗪环的甲斯卡林类似物的合成及其对中枢神经系统的作用。

  摘要：

  在一系列甲斯卡林类似物（I-IV）中，已经实现了在同一分子中将3,4,5-三甲氧基苯基与哌嗪或高哌嗪环的结构并置，作为对该七元药理学性质进行研究的一部分过氢-1,4-二氮杂（（高哌嗪）。合成了类似的六元哌嗪，并作为参考物质进行了测试，以确定七元环是否具有特殊性质。对中枢神经系统作用的各种药理试验表明，杂环取代甲卡斯汀中的氨基会显着改变生物活性。特别地，哌嗪和高哌嗪衍生物均显示出大致相同的镇静活性。

  DOI：

  10.1002/jps.2600720324

文献信息

• Benzylpiperazine derivatives. II. Syntheses and cerebral vasodilating activities of 1-((3-alkyl-3-hydroxy-3-phenyl)propyl)-4-benzylpiperazine derivatives.
  作者：HIROSHI OHTAKA、YOSHIAKI FUJIMOTO、KENJI YOSHIDA、TOSHIRO KANAZAWA、KEIZO ITO、GORO TSUKAMOTO

  DOI：10.1248/cpb.35.2782

  日期：——

  Analogs of 1-[ (3-alkyl-3-hydroxy-3-phenyl) propyl]-4- (2, 3, 4-trimethoxybenzyl) piperazine (1) were prepared and tested for cerebral vasodilating activity. It was found that the potency depends positively on the number of methoxyl groups on the benzyl moiety, and the homopiperazine analogs seem to be equipotent to the corresponding piperazines. From the standpoints of potency and ease of synthesis, 8k was selected for further study. Further analogs, which have various substituents in place of the benzyl moiety of 8k, were prepared and tested for cerebral vasodilating activity. These analogs were less potent than 8k. It was suggested that the benzyl moiety of 8k plays an important role in the high cerebral vasodilating activity.

  1-[ (3-烷基-3-羟基-3-苯基)丙基]-4- (2, 3, 4-三甲氧基苯基)哌嗪（1）的类似物被制备并测试了其脑血管扩张活性。研究发现，活性强度与苄基部分上的甲氧基团数量呈正相关，而同脉哌嗪类的类似物似乎与相应的哌嗪类同样具有活性。从活性和合成简便性来看，选定了8k进行进一步研究。随后制备了在8k的苄基部分替换为各种取代基的其他类似物，并测试了其脑血管扩张活性。这些类似物的活性均低于8k。研究者认为，8k的苄基部分在其高脑血管扩张活性中起着重要作用。
• Heterocyclic compounds
  申请人：John Wyeth & Brother Limited

  公开号：US03992389A1

  公开（公告）日：1976-11-16

  A group of heterocyclic compounds useful in the treatment of disorders and diseases of the cardiovascular system and/or in the treatment of superficial and deep allergic phenomena is described. These compounds are piperidine compounds linked by the nitrogen atom to a substituted or unsubstituted phenyl radical through the intermediary of a group selected from a lower-alkylene radical, a mono-keto lower alkylene radical or a hydroxy-lower-alkylene radical, or a bivalent radical of the formula ##EQU1## or --O--(lower-alkylene)-. The piperidine rings are further substituted by a benzamido, substituted benzamido or cyclohexylcarboxamido residue.

  本文描述了一组杂环化合物，可用于治疗心血管系统的疾病和紫外线过敏反应。这些化合物是由哌啶化合物组成，通过氮原子与一个取代或未取代的苯基团连接，中间通过从低碳烷基，单羰基低碳烷基或羟基-低碳烷基中选择的基团或公式##EQU1##或-O-(低碳烷基)-的双价基团连接。哌啶环还进一步取代了苯甲酰胺基团，取代苯甲酰胺基团或环己基羧酰胺基团。
• Pharmaceutical compositions and methods of treating hypertension
  申请人：John Wyeth & Brother Limited

  公开号：US04029801A1

  公开（公告）日：1977-06-14

  Pharmaceutical compositions containing a group of heterocyclic compounds and their use in treatment of disorders and diseases of the cardiovascular system and/or in the treatment of superficial and deep allergic phenomena is described. These compounds used in the composition and/or methods are piperidine compounds linked by the nitrogen atom to a substituted or unsubstituted cycloalkyl, aryl or heterocyclic radical through the intermediary of a group selected from a lower-alkylene radical, a monoketo lower-alkylene radical or a hydroxy-lower-alkylene radical, or a bivalent radical of the formula --NH.CO.(CH.sub.2).sub.n -- where n is 1, 2 or 3, ##STR1## or --0-(lower-alkylene)--. The piperidine ring is further substituted by an acylamino residue.

  本文描述了含有一组杂环化合物的制药组合物，以及它们在治疗心血管系统的疾病和障碍和/或治疗浅表和深部过敏现象中的用途。这些化合物在组合物和/或方法中使用，是通过从下列选项中选择的基团，将哌啶化合物与取代或未取代的环烷基、芳基或杂环基连接起来的：低烷基基团、单酮低烷基基团或羟基低烷基基团，或者是公式--NH.CO.（CH.sub.2）.sub.n --，其中n为1、2或3，##STR1##或--0-(低烷基)--。哌啶环进一步被酰胺残基取代。
• Piperidino compounds
  申请人：John Wyeth & Brother Limited

  公开号：US04046767A1

  公开（公告）日：1977-09-06

  Novel piperidine compounds and their use in treatment of disorders and diseases of the cardiovascular system and/or in the treatment of superficial and deep allergic phenomena is described. These compounds are piperidine compounds linked by the nitrogen atom to cycloalkyl or a substituted or unsubstituted phenyl radical through the intermediary of a lower-alkylene radical. The piperidine ring is further substituted by an acylamino residue.

  本发明描述了新型哌啶类化合物及其在治疗心血管系统疾病和/或治疗浅表和深部过敏现象中的应用。这些化合物是哌啶类化合物，通过氮原子与环烷基或取代或未取代的苯基通过较低烷基的中介连接。哌啶环进一步被酰胺基残基取代。
• Isoquinuclidine-based expectorants. Synthesis and biological activities of N-alkoxybenzylisoquinuclidines
  作者：M Yokota、E Takizawa、Y Ohkura、C Fukai、T Tomiyama

  DOI：10.1016/s0223-5234(97)81675-3

  日期：1997.5

  N-Di-, trialkoxybenzylisoquinuclidines and related compounds were synthesized and evaluated for expectorant activities. Structure-activity relationship investigations in this series showed that both the trialkoxyphenyl ring and the basic nitrogen atom at the benzylic position were necessary for activity. N-Trialkoxybenzylisoquinuclidines 7a, 7c, 7d, 7f and 7g significantly increased bronchial secretion, and ethoxy derivative 7c showed the highest activity in these compounds. The n-propyloxy derivatives 7d and 7f also accelerated bronchoalveolar surfactant secretion with about two to four times more activity than ambroxol (7d and 7f; ED50 = 27.5 and 15.5 mg/kg po, respectively); however, compounds 7a, 7c and 7g were less active than ambroxol. Compounds 7d and 7f were selected for further examination. These compounds displayed antioxidant activity in vitro (7d and 7f, IC50 = 48.0 and 66.0 mu M, respectively). Compound 7d also showed inhibition on bradykinin- or antigen-induced airway inflammation in guinea pigs. These findings suggest that compounds 7d and 7f are potent expectorants with antiinflammatory activity.